Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (544 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: disordercardiovascular hepaticneurologic oror psychiatricrenal respiratory
  Phrases that lowered it: healthysingle dosescreeningopen labelan open
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Primary purpose: health services research (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 10.1% (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Blinding: none (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 113 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor's past trials: 335 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Sex: male (lowers risk) · Who can join
• Maximum age: 50 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug NCT01124747 · started 2010 · scored riskier than 1% of active trials completed
• Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606 NCT00757341 · started 2008 · scored riskier than 1% of active trials completed
• 14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man NCT01176201 · started 2010 · scored riskier than 1% of active trials completed
• Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M NCT02023606 · started 2013 · scored riskier than 1% of active trials completed
• A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects NCT01406132 · started 2009 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.